Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity-Reference-Cited by-同舟云学术

Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity

Published:2019-08 Issue:35 Volume:37 Page:4823-4829
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Innis Bruce L.^ORCID,Berlanda Scorza Francesco,Blum Jeremy S.,Jain Varsha K.,Older Aguilar Anastazia,Post Diane J.,Roberts Paul C.,Wairagkar Niteen,White Janet,Bresee Joseph

Funder

Bill and Melinda Gates Foundation

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference27 articles.

1. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases;Erbelding;J Infect Dis,2018

2. Nomenclature for immune correlates of protection after vaccination;Plotkin;Clin Infect Dis,2012

3. Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations;Innis;Vaccine,2019

4. World Health Organization. WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines. May 2017. ISBN 978-92-4-151246-6.

5. The Bill and Melinda Gates Foundation. Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development. 2018, June 22

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses;Vaccines;2023-10-09

2. The WE SENSE study protocol: A controlled, longitudinal clinical trial on the use of wearable sensors for early detection and tracking of viral respiratory tract infections;Contemporary Clinical Trials;2023-05

3. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2;Nature Materials;2023-01-30

4. Influenza;The Lancet;2022-08

5. Materials‐based vaccines for infectious diseases;WIREs Nanomedicine and Nanobiotechnology;2022-06-16